Instadose (INSD) Responds to SEC Suspension of Trading on OTC Markets

Rhea-AI Summary

Instadose Pharma Corp. (OTC PINK:INSD) announced a trading suspension by the SEC from November 24, 2021 to December 8, 2021. This decision stems from concerns regarding the accuracy of publicly available information about the company. Terry Wilshire, CEO, stated the company will cooperate fully with the SEC and provide updates as they become available.

The suspension aims to protect investor interests and ensure fair market conditions.

Positive

• None.

Negative

• Trading suspension may lead to reduced investor confidence.
• Concerns regarding information accuracy could impact reputation.
• Potential regulatory scrutiny could result in further complications.

CHESAPEAKE, VA / ACCESSWIRE / November 24, 2021 / Instadose Pharma Corp. (OTC PINK:INSD) today announced that on November 23, 2021, the Company was notified by the SEC that it had ORDERED, pursuant to Section 12(k) of the Securities Exchange Act of 1934, that trading in the securities of the above-listed Company is suspended for the period from 9:30 a.m. EDT on November 24, 2021, through 11:59 p.m. EDT on December 8, 2021.

Terry Wilshire, Chief Executive Officer of Instadose Pharma Corp. said: "The Company will work with its SEC counsel and will fully cooperate with the SEC in a timely manner. We will provide additional information and updates as permitted, to our shareholders and the markets as the matter develops."

It appears to the Securities and Exchange Commission that the public interest and the protection of investors require a suspension in the trading of the securities of Instadose Pharma Corp. ("Instadose Pharma") (CIK No. 0001697587), a Nevada corporation whose principal place of business is listed as Chesapeake, Virginia, because of questions and concerns regarding the adequacy and accuracy of information about Instadose Pharma in the marketplace.

For more information please contact:

info@instadosepharma.com

SOURCE: Instadose Pharma Corp.

View source version on accesswire.com:
https://www.accesswire.com/674646/Instadose-INSD-Responds-to-SEC-Suspension-of-Trading-on-OTC-Markets

FAQ

What caused the trading suspension for Instadose Pharma Corp (INSD)?

The SEC ordered the suspension due to concerns about the adequacy and accuracy of information regarding Instadose Pharma in the marketplace.

When is the trading suspension for INSD set to end?

The trading suspension for Instadose Pharma Corp is scheduled to last from November 24, 2021, until December 8, 2021.

What will Instadose Pharma Corp do during the SEC suspension?

Instadose Pharma Corp will work with SEC counsel and cooperate fully with the SEC while providing updates to shareholders as allowed.

How might the SEC suspension affect investors in Instadose Pharma Corp (INSD)?

The suspension could lead to decreased investor confidence and potential reputational damage, raising concerns among shareholders.